Jiangsu Pacific Meinok Biopharmaceutical

Jiangsu Pacific Meinok Biopharmaceutical is a clinical-stage biotechnology company based in Taizhou, China, specializing in the development of high-end biological drugs. Founded in 2011, the company focuses on monoclonal antibodies and recombinant proteins targeting oncology, ophthalmology, and autoimmune diseases. Its lead candidate, M-001, is a bevacizumab biosimilar that has advanced into Phase 3 clinical trials for metastatic colorectal cancer and non-small cell lung cancer. Pacific Meinok operates integrated research, development, and large-scale GMP manufacturing facilities within the China Medical City industrial cluster. The company aims to provide high-efficacy, affordable biological therapeutics for both domestic and international markets.